Primary pulmonary hypertension: Molecular basis and potential for therapy

Expert Reviews in Molecular Medicine

Volumn 6, Issue 6, 2004, Pages

  Rudarakanchana, Nung ^a   Morrell, Nicholas W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Bone morphogenetic protein type II receptor; p38 mitogen activated protein kinase; PPH; Primary pulmonary hypertension; Smads

Indexed keywords

AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCIUM CHANNEL BLOCKING AGENT; COCAINE; DEXFENFLURAMINE; ENDOGLIN; ENDOTHELIN RECEPTOR ANTAGONIST; ESTROGEN; FENFLURAMINE; GROWTH DIFFERENTIATION FACTOR 5; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOGENIC PROTEIN 1; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RAPESEED OIL; SEROTONIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNINDEXED DRUG; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AUTOIMMUNE DISEASE; CHRONIC GRAFT REJECTION; DIARRHEA; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FACE PAIN; FLUSHING; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; INCIDENCE; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; NAUSEA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOM; THROMBOCYTE AGGREGATION INHIBITION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; SINAPIS ARVENSIS;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEROTONIN; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 31044455086     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399404007483     Document Type: Review

References (75)

1. World Health Organisation 3rd World Symposium for Pulmonary Arterial Hypertension (Venice, 2003). Journal of the American College of Cardiologists (in press)
2. Dresdale, D.T., S.M. and Michtom, R.J. (1951) Primary pulmonary hypertension - I: clinical and hemodynamic study. Am J Med 11, 686-701
3. Rubin, L.J. (1997) Primary pulmonary hypertension. N Engl J Med 336, 111-117,
4. Gaine, S.P. and Rubin, L.J. (1998) Primary pulmonary hypertension. Lancet 352, 719-725,
5. Yi, E.S. et al. (2000) Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162, 1577-1586,
6. Orte, C. et al. (2000) Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192, 379-384,
7. Smith, P. et al. (1990) The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160, 111-121,
8. Abenhaim, L. et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335, 609-616,
9. Abenhaim, L. and Humbert, M. (1999) Pulmonary hypertension related to drugs and toxins. Curr Opin Cardiol 14, 437-441,
10. Opravil, M. et al. (1997) HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155, 990-995,
11. Cool, C.D. et al. (2003) Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349, 1113-1122,
12. Morse, J.H., Horn, E.M. and Barst, R.J. (1999) Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest 116, 847,
13. Monnery, L., Nanson, J. and Charlton, G. (2001) Primary pulmonary hypertension in pregnancy; a role for novel vasodilators. Br J Anaesth 87, 295-298,
14. Dresdale, D.T., Michtom, R.J. and Schultz, M. (1954) Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 30, 195-207,
15. Rich, S. et al. (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107, 216-223,
16. Loyd, J.E. et al. (1995) Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 152, 93-97,
17. Nichols, W.C. et al. (1997) Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 15, 277-280,
18. Deng, Z. et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67, 737-744,
19. Lane, K.B. et al. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 26, 81-84,
20. Machado, R.D. et al. (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68, 92-102,
21. Thomson, J.R. et al. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPRII a receptor member of the TGF-beta family. J Med Genet 37, 741-745,
22. Trembath, R.C. et al. (2001) Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345, 325-334,
23. Shovlin, C.L. and Letarte, M. (1999) Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 54, 714-729,
24. Kawabata, M., Imamura, T. and Miyazono, K. (1998) Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9, 49-61,
25. Sakou, T. (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22, 591-603,
26. Dorai, H., Vukicevic, S. and Sampath, T.K. (2000) Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184, 37-45,
27. Nakaoka, T. et al. (1997) Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 100, 2824-2832,
28. Morrell, N.W. et al. (2001) Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 104, 790-795,
29. Beppu, H. et al. (2000) BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 221, 249-258,
30. Yang, X. et al. (1999) Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 126, 1571-1580,
31. Massague, J., Blain, S.W. and Lo, R.S. (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309,
32. Nohe, A. et al. (2002) The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277, 5330-5338,
33. Nohno, T. et al. (1995) Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J Biol Chem 270, 22522-22526,
34. ten Dijke, P. et al. (1994) Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 269, 16985-16988,
35. Miyazono, K. (2000) TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev 11, 15-22,
36. Massague, J. and Chen, Y.G. (2000) Controlling TGF-beta signaling. Genes Dev 14, 627-644,
37. Wrana, J.L. and Attisano, L. (2000) The Smad pathway. Cytokine Growth Factor Rev 11, 5-13,
38. Raftery, L.A. and Sutherland, D.J. (1999) TGF-beta family signal transduction in Drosophila development: from Mad to Smads. Dev Biol 210, 251-268,
39. Itoh, F. et al. (2001) Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. Embo J 20, 4132-4142,
40. Roberts, A.B. (2002) The ever-increasing complexity of TGF-beta signaling. Cytokine Growth Factor Rev 13, 3-5,
41. Welsh, D.J. et al. (2001) Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care Med 164, 282-289,
42. Kretzschmar, M., Doody, J. and Massague, J. (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smadl. Nature 389, 618-622,
43. Shi, Y. and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700,
44. Whitman, M. (1997) Signal transduction. Feedback from inhibitory SMADs. Nature 389, 549-551,
45. Yeager, M.E. et al. (2001) Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 88, E2-E11,
46. Botney, M.D., Bahadori, L. and Gold, L.I. (1994) Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 144, 286-295,
47. Shovlin, C.L. et al. (1997) Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet 61, 68-79,
48. Eddahibi, S. et al. (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108, 1141-1150,
49. Herve, P. et al. (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99, 249-254,
50. Rich, S. et al. (2000) Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117, 870-874,
51. Launay, J.M. et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8, 1129-1135,
52. Lee, S.L., Wang, W.W. and Fanburg, B.L. (2001) Dexfenfluramine as a mitogen signal via the formation of superoxide anion. Faseb J 15, 1324-1325,
53. Eddahibi, S. et al. (2000) Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest 105, 1555-1562,
54. Eddahibi, S. et al. (2001) Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther 297, 148-154,
55. Yuan, J.X. et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98, 1400-1406,
56. Yuan, X.J. et al. (1998) Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 351, 726-727,
57. Weir, E.K. et al. (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94, 2216-2220,
58. Christman, B.W. et al. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327, 70-75,
59. Giaid, A. et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328, 1732-1739,
60. Giaid, A. and Saleh, D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333, 214-221,
61. Zhao, Y.D. et al. (2003) Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 92, 984-991,
62. Du, L. et al. (2003) Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348, 500-509,
63. Atkinson, C. et al. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678,
64. Grunig, E. et al. (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102, 1145-1150,
65. Rudarakanchana, N. et al. (2002) Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 11, 1517-1525,
66. Nishihara, A. et al. (2002) Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 13, 3055-3063,
67. Hoeper, M.M. et al. (2002) New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 165, 1209-1216,
68. Rich, S. and Brundage, B.H. (1987) High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circularion 76, 135-141,
69. Rich, S., Kaufmann, E. and Levy, P.S. (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327, 76-81,
70. Higenbottam, T.W. et al. (1993) Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 70, 366-370,
71. Barst, R.J. et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334, 296-302,
72. Barst, R.J. et al. (1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121, 409-415,
73. Palmer, S.M. et al. (1998) Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 113, 237-240,
74. Prasad, S., Wilkinson, J. and Gatzoulis, M.A. (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343, 1342,
75. Kshettry, V.R. et al. (1996) Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 110, 704-709,